Metodebevisregister

Bayesian Phase I clinical trial

A Bayesian Phase I clinical trial uses prior probability models and sequential Bayes updating to find the maximum tolerated dose (MTD) of a new agent. Unlike the traditional 3+3 rule-based escalation, the Bayesian approach revises a dose-toxicity curve continuously as each patient's outcome is observed, allowing faster convergence to the true MTD while minimising exposure of patients to unsafe or subtherapeutic doses.

Sources recorded, not reviewed

Kilderegister

Siteringer kopiert ordrett fra metodens kilderegister. Ingen påstandsnivåverifisering er underforstått fra dem.

Bayesian Phase I Clinical Trial (Dose-Finding Design)

Taksonomisk metoderegister · process-pipeline / epidemiology

O'Quigley, J., Pepe, M., & Fisher, L. (1990). Continual reassessment method: a practical design for phase 1 clinical trials in cancer. Biometrics, 46(1), 33–48. · DOI 10.2307/2531628
Chevret, S. (Ed.). (2006). Statistical Methods for Dose-Finding Experiments. Wiley. · ISBN 978-0470861769

Åpne full metode

Kuraterte påstander

Påstander lagret i bevishovedboken, hver med sin egen vurdering.

Ingen kuraterte påstander ennå

Denne visningen finner ikke opp en påstandsvurdering når hovedboken ikke har noen.

Relaterte metoder

Generert fra metodegrafen og vist som maskinforslåtte relasjoner – ingen bevispåstand er underforstått.

Taxonomic bucketAdaptive Phase I Clinical Trialmachine-suggested · Relational suggestion, not evidence.Taxonomic bucketAdaptive Randomized Clinical Trialmachine-suggested · Relational suggestion, not evidence.Taxonomic bucketBayesian Randomized Clinical Trialmachine-suggested · Relational suggestion, not evidence.Taxonomic bucketDose-Response Analysismachine-suggested · Relational suggestion, not evidence.Taxonomic bucketPhase I Clinical Trialmachine-suggested · Relational suggestion, not evidence.